Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 204 participants.

Also called NCT03672097

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 204 participants (enrolled count) (from the registry)
Sponsor
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company (from the registry)
Registry
  • NCT NCT03672097
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03672097. Allocation not applicable; no masking; primary purpose treatment. Start 2018-10-16 (actual); primary completion 2020-08-19 (actual). Results posted on 2021-11-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
Condition
Acute Coronary Syndrome (ACS)
Intervention (Drug)
Prasugrel
Lead sponsor
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company (class: industry)

Record details

Record id
cardio:ct-nct03672097
Content hash
9436ae4010a1f306e6eb75581074dcec1db14be672eb983d84225f7e9fa5e6f1